Here's something you might be interested in.
People are paying around $1,000 to get a test that will give a glimpse of their genome -- whether they are prone to cancer, Alzheimer's, etc. San Diego's Illumina is one of the companies providing smart chips for these tests, which are marketed by Iceland's Decode Genetics, and the Bay Area's 23andMe (funded by Google). Illumina's stock has been strong of late. But is it a fad? "You are wasting your money," says Christine Patch, a member of Britain's Human Genetics Commission, according to Reuters. Paul Pharoah from the department of oncology at Cambridge says researchers don't know enough about genes for these tests to be useful.
People are paying around $1,000 to get a test that will give a glimpse of their genome -- whether they are prone to cancer, Alzheimer's, etc. San Diego's Illumina is one of the companies providing smart chips for these tests, which are marketed by Iceland's Decode Genetics, and the Bay Area's 23andMe (funded by Google). Illumina's stock has been strong of late. But is it a fad? "You are wasting your money," says Christine Patch, a member of Britain's Human Genetics Commission, according to Reuters. Paul Pharoah from the department of oncology at Cambridge says researchers don't know enough about genes for these tests to be useful.